Tarsus Pharmaceuticals Stock Alpha and Beta Analysis
| TARS Stock | USD 49.97 0.06 0.12% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Tarsus Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Tarsus Pharmaceuticals over a specified time horizon. Remember, high Tarsus Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Tarsus Pharmaceuticals' market risk premium analysis include:
Beta 0.55 | Alpha 0.0103 | Risk 3.48 | Sharpe Ratio (0.02) | Expected Return (0.08) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Tarsus |
Tarsus Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Tarsus Pharmaceuticals market risk premium is the additional return an investor will receive from holding Tarsus Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Tarsus Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Tarsus Pharmaceuticals' performance over market.| α | 0.01 | β | 0.55 |
Tarsus Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Tarsus Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Tarsus Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Tarsus Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Tarsus Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Tarsus Pharmaceuticals shares will generate the highest return on investment. By understating and applying Tarsus Pharmaceuticals stock market price indicators, traders can identify Tarsus Pharmaceuticals position entry and exit signals to maximize returns.
Tarsus Pharmaceuticals Return and Market Media
The median price of Tarsus Pharmaceuticals for the period between Mon, Dec 23, 2024 and Sun, Mar 23, 2025 is 50.85 with a coefficient of variation of 8.03. The daily time series for the period is distributed with a sample standard deviation of 4.02, arithmetic mean of 50.01, and mean deviation of 3.46. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Goodrich Katherine of 10000 shares of Tarsus Pharmaceuticals at 46.51 subject to Rule 16b-3 | 02/14/2025 |
2 | Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies Board of Directors at 2025 Annual Meeting | 02/19/2025 |
3 | Tarsus Pharmaceuticals Inc Q4 2024 Earnings Call Highlights Strong Sales Growth and ... | 02/26/2025 |
4 | Tarsus Pharmaceuticals Earns Buy Rating from HC Wainwright | 02/28/2025 |
5 | Acquisition by Lin Elizabeth Yeu of 10045 shares of Tarsus Pharmaceuticals subject to Rule 16b-3 | 03/05/2025 |
6 | Tarsus Pharmaceuticals Inc to Participate in Barclays Global Healthcare Conference | 03/06/2025 |
7 | Disposition of 7000 shares by Goldberg Andrew D. of Tarsus Pharmaceuticals at 12.89 subject to Rule 16b-3 | 03/07/2025 |
8 | Aura Biosciences and Tarsus Pharmaceuticals Financial Survey | 03/10/2025 |
9 | Tarsus Announces Pricing of Upsized 125.0 Million Public Offering | 03/13/2025 |
10 | Disposition of 4790 shares by Mottiwala Aziz of Tarsus Pharmaceuticals subject to Rule 16b-3 | 03/14/2025 |
11 | Disposition of 8019 shares by Jeffrey Farrow of Tarsus Pharmaceuticals subject to Rule 16b-3 | 03/17/2025 |
12 | Disposition of 1254 shares by Jeffrey Farrow of Tarsus Pharmaceuticals at 47.4 subject to Rule 16b-3 | 03/19/2025 |
13 | Disposition of 1186 shares by Jeffrey Farrow of Tarsus Pharmaceuticals at 50.11 subject to Rule 16b-3 | 03/20/2025 |
14 | Disposition of 2543 shares by Seshadri Neervannan of Tarsus Pharmaceuticals at 47.4 subject to Rule 16b-3 | 03/23/2025 |
About Tarsus Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Tarsus or other stocks. Alpha measures the amount that position in Tarsus Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 (projected) | |
| Payables Turnover | 0.0878 | 0.46 | 0.49 |
| Days Of Inventory On Hand | 711.9 | 74.56 | 70.83 |
Tarsus Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Tarsus Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tarsus Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Tarsus Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Tarsus Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Tarsus Pharmaceuticals' management manipulating its earnings.
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 11th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Tarsus Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.